<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Glaxosmithkline Plc — News on 6ix</title>
<link>https://6ix.com/company/glaxosmithkline-plc</link>
<description>Latest news and press releases for Glaxosmithkline Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 05:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/glaxosmithkline-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e42778dffbe2df127936.webp</url>
<title>Glaxosmithkline Plc</title>
<link>https://6ix.com/company/glaxosmithkline-plc</link>
</image>
<item>
<title>Q1 results lower year on year, as expected; Comprehensive action plan underway to address market challenges</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/q1-results-lower-year-on-year-as-expected-comprehensive-action-plan-underway-to-address-market-challenges</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/q1-results-lower-year-on-year-as-expected-comprehensive-action-plan-underway-to-address-market-challenges</guid>
<pubDate>Wed, 29 Apr 2026 05:00:00 GMT</pubDate>
<description>Regulated information Growth in adult care offset by continued softness in baby care and expected decline in contract manufacturing, resulting in 4% LFL revenue decrease year on year; Capacity ramp‑up continued in adult care to support future growth;Adjusted EBITDA margin of 9.1%, down 2.2pp year on year, and stable quarter on quarter; Efficiency initiatives accelerated to improve profitability;Net debt reduced by a further 5% over the quarter to €550 million, strengthening the balance sheet; Ac</description>
</item>
<item>
<title>Human Papillomavirus Market Research Report 2025-2035, Competitive Analysis of Key Players - GlaxoSmithKline, Merck, and Serum Institute of India</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/human-papillomavirus-market-research-report-2025-2035-competitive-analysis-of-key-players-glaxosmithkline-merck-and-serum-institute-of-india</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/human-papillomavirus-market-research-report-2025-2035-competitive-analysis-of-key-players-glaxosmithkline-merck-and-serum-institute-of-india</guid>
<pubDate>Tue, 28 Apr 2026 08:04:00 GMT</pubDate>
<description>The Human Papillomavirus (HPV) market is in a growth phase, driven by high vaccine adoption and innovative therapeutic strategies targeting HPV-related cancers like cervical and oropharyngeal. Key drivers include advancements in molecular diagnostics, next-gen vaccines, and government-supported immunization initiatives. North America leads the market with strong uptake and infrastructure, followed by Europe and rapidly expanding Asia-Pacific. However, challenges such as vaccine hesitancy and hig</description>
</item>
<item>
<title>Efimosfermin granted US/EU regulatory designations</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/efimosfermin-granted-useu-regulatory-designations</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/efimosfermin-granted-useu-regulatory-designations</guid>
<pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
<description>GSK announced that its investigational liver therapy, efimosfermin, has received Breakthrough Therapy Designation from the US FDA and Priority Medicines (PRIME) Designation from the EMA for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Phase II data showed that once-monthly efimosfermin improved liver fibrosis and MASH resolution in patients with moderate to advanced fibrosis, with a well-tolerated safety profile. These designations acknowledge the significant unmet m</description>
</item>
<item>
<title>Blenrep approved in China for 2L+ multiple myeloma</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/blenrep-approved-in-china-for-2l-multiple-myeloma</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/blenrep-approved-in-china-for-2l-multiple-myeloma</guid>
<pubDate>Mon, 20 Apr 2026 06:00:00 GMT</pubDate>
<description>GSK plc announced that Blenrep (belantamab mafodotin) has been approved in China for the treatment of relapsed or refractory multiple myeloma in adults who have received at least one prior line of therapy. This approval, following priority review and Breakthrough Therapy Designation, is supported by data from the DREAMM-7 trial, which demonstrated that the Blenrep combination nearly tripled median progression-free survival and showed a 42% reduction in the risk of death compared to a daratumumab</description>
</item>
<item>
<title>GSK completes acquisition of 35Pharma Inc.</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/gsk-completes-acquisition-of-35pharma-inc</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/gsk-completes-acquisition-of-35pharma-inc</guid>
<pubDate>Wed, 15 Apr 2026 06:12:00 GMT</pubDate>
<description>GSK plc has completed its acquisition of 35Pharma Inc. for $950 million, gaining 100% equity in the Canadian biopharmaceutical company. This acquisition includes HS235, a novel protein-based therapeutic targeting pulmonary hypertension (PH) by acting on the activin receptor signalling pathway, a market projected to reach $18 billion by 2032. HS235 aims to address limitations of current treatments by potentially reducing bleeding risks and offering metabolic benefits, with proof-of-concept trials</description>
</item>
<item>
<title>GSK presents positive data for BEHOLD 1 B7 H4 ADC</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/gsk-presents-positive-data-for-behold-1-b7-h4-adc</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/gsk-presents-positive-data-for-behold-1-b7-h4-adc</guid>
<pubDate>Mon, 13 Apr 2026 06:00:00 GMT</pubDate>
<description>GSK announced positive Phase 1 BEHOLD-1 trial data for mocertatug rezetecan (Mo-Rez), a novel B7-H4-targeted antibody-drug conjugate, showing confirmed objective response rates of 62% in platinum-resistant ovarian cancer and 67% in recurrent or advanced endometrial cancer. These promising efficacy and safety results, with manageable adverse events, support the initiation of five pivotal Phase III trials in 2026, aiming to address limited treatment options for these gynaecological cancers.
</description>
</item>
<item>
<title>Exdensur approved for CRSwNP in China</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/exdensur-approved-for-crswnp-in-china</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/exdensur-approved-for-crswnp-in-china</guid>
<pubDate>Wed, 08 Apr 2026 06:00:00 GMT</pubDate>
<description>GSK plc announced that China's National Medical Products Administration has approved Exdensur (depemokimab) for chronic rhinosinusitis with nasal polyps (CRSwNP) in adults, following its recent approval for severe asthma in China. This approval, based on the ANCHOR trials, showed clinically meaningful improvements in nasal polyp size and nasal obstruction, with depemokimab demonstrating a favorable safety profile comparable to placebo. Exdensur is the first and only ultra-long-acting biologic fo</description>
</item>
<item>
<title>ViiV completes changes to minority shareholding</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/viiv-completes-changes-to-minority-shareholding</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/viiv-completes-changes-to-minority-shareholding</guid>
<pubDate>Wed, 01 Apr 2026 06:00:00 GMT</pubDate>
<description>GSK plc and Shionogi & Co., Ltd. have completed a transaction where Shionogi increased its economic interest in ViiV Healthcare to 21.7%, with GSK retaining a 78.3% majority stake, following Pfizer's exit. ViiV Healthcare issued new shares to Shionogi for $2.125 billion, with Pfizer receiving $1.875 billion and GSK receiving a $0.250 billion special dividend. The Pfizer put option liability previously recorded in GSK's accounts has been extinguished.
Disclaimer*</description>
</item>
<item>
<title>Bepirovirsen accepted for review in China</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/bepirovirsen-accepted-for-review-in-china</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/bepirovirsen-accepted-for-review-in-china</guid>
<pubDate>Mon, 30 Mar 2026 06:05:00 GMT</pubDate>
<description>GSK plc announced that China's National Medical Products Administration has accepted for review bepirovirsen, an investigational treatment for chronic hepatitis B, which affects an estimated 75 million people in China. This submission is supported by positive Phase III B-Well trial results demonstrating statistically significant functional cure rates, a significant improvement over the current 1% cure rate with standard of care. Bepirovirsen, which previously received Breakthrough Therapy design</description>
</item>
<item>
<title>Exdensur approved for severe asthma in China</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/exdensur-approved-for-severe-asthma-in-china</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/exdensur-approved-for-severe-asthma-in-china</guid>
<pubDate>Mon, 30 Mar 2026 06:00:00 GMT</pubDate>
<description>GSK plc announced that China's National Medical Products Administration has approved Exdensur (depemokimab) for severe asthma with an eosinophilic phenotype in adults and children aged 12 and older, marking the first ultra-long-acting biologic for this condition in China. The approval, based on the SWIFT trials, showed depemokimab significantly reduced exacerbations, with a 58% and 48% reduction in annualised rates in SWIFT-1 and SWIFT-2 respectively, and a 72% reduction in hospitalisation-requi</description>
</item>
<item>
<title>Bepirovirsen accepted for review by the EMA</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/bepirovirsen-accepted-for-review-by-the-ema</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/bepirovirsen-accepted-for-review-by-the-ema</guid>
<pubDate>Fri, 27 Mar 2026 07:00:00 GMT</pubDate>
<description>GSK plc announced that the European Medicines Agency has accepted for review its marketing authorisation application for bepirovirsen, an investigational treatment for chronic hepatitis B. This submission is supported by positive results from the pivotal Phase III B-Well trials, which demonstrated statistically significant and clinically meaningful functional cure rates for bepirovirsen in combination with standard of care, compared to standard of care alone. Chronic hepatitis B affects an estim</description>
</item>
<item>
<title>Admission to Trading</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/admission-to-trading-8</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/admission-to-trading-8</guid>
<pubDate>Mon, 23 Mar 2026 15:00:00 GMT</pubDate>
<description>GSK plc has announced the admission of 96,525 ordinary shares of 31¼ pence each to trading on the London Stock Exchange's Main Market. These shares, admitted under existing block listing arrangements for the GlaxoSmithKline plc Share Save Plans 2012 and 2022, are fully fungible with the company's existing ordinary shares. Following this admission, the total number of ordinary shares admitted to trading stands at 4,316,176,278. This notification covers the period from 23 January 2026 to 20 March </description>
</item>
<item>
<title>GSK Lung Cancer ADC Gets Japan Orphan Drug Status</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/gsk-lung-cancer-adc-gets-japan-orphan-drug-status</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/gsk-lung-cancer-adc-gets-japan-orphan-drug-status</guid>
<pubDate>Mon, 23 Mar 2026 07:00:00 GMT</pubDate>
<description>GSK plc announced that its B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, has received Orphan Drug Designation in Japan for the treatment of small-cell lung cancer (SCLC), supported by early clinical data showing durable responses in extensive-stage SCLC patients. This marks the sixth global regulatory designation for risvutatug rezetecan, which is being developed for various solid tumours and has previously received designations from the US FDA and EMA, including Breakthrough The</description>
</item>
<item>
<title>Lynavoy (linerixibat) approved by US FDA</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/lynavoy-linerixibat-approved-by-us-fda</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/lynavoy-linerixibat-approved-by-us-fda</guid>
<pubDate>Thu, 19 Mar 2026 12:00:00 GMT</pubDate>
<description>GSK plc announced that the US FDA has approved Lynavoy (linerixibat) for cholestatic pruritus in adult patients with primary biliary cholangitis (PBC), marking the first US approval for this indication. This ileal bile acid transporter inhibitor, which reduces itch drivers, is based on positive Phase III GLISTEN trial data, with regulatory reviews ongoing in the EU, UK, Canada, and China. GSK previously announced a license agreement for worldwide rights to linerixibat with Alfasigma S.p.A., whic</description>
</item>
<item>
<title>US FDA approves Arexvy for adults 18-49 AIR</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/us-fda-approves-arexvy-for-adults-18-49-air</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/us-fda-approves-arexvy-for-adults-18-49-air</guid>
<pubDate>Fri, 13 Mar 2026 10:31:00 GMT</pubDate>
<description>GSK plc announced that the US FDA has expanded the approved age indication for its RSV vaccine, Arexvy, to include adults aged 18 to 49 years who are at increased risk for lower respiratory tract disease caused by RSV. This expansion is supported by data showing a non-inferior immune response compared to older adults, with a safety profile consistent with previous findings. The annual RSV burden in this younger adult demographic includes an estimated 17,000 hospitalisations and 277,000 emergency</description>
</item>
<item>
<title>Board Committee Change</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/board-committee-change-5</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/board-committee-change-5</guid>
<pubDate>Mon, 09 Mar 2026 15:00:00 GMT</pubDate>
<description>GSK plc announced a change to its Board committee membership, effective March 9, 2026, with Elizabeth McKee Anderson appointed as a member of the Corporate Responsibility Committee, in addition to her existing roles on the Audit & Risk and Remuneration committees.
Disclaimer*</description>
</item>
<item>
<title>GSK and Alfasigma agree global linerixibat rights</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/gsk-and-alfasigma-agree-global-linerixibat-rights</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/gsk-and-alfasigma-agree-global-linerixibat-rights</guid>
<pubDate>Mon, 09 Mar 2026 07:00:00 GMT</pubDate>
<description>GSK plc has entered into a licensing agreement with Alfasigma S.p.A. for worldwide exclusive rights to develop, manufacture, and commercialize linerixibat, an investigational treatment for cholestatic pruritus in primary biliary cholangitis. Under the terms, GSK will receive an upfront payment of $300 million, an additional $100 million upon US FDA approval expected by March 24, 2026, $20 million upon EU and UK approval, and up to $270 million in sales-based milestones, along with tiered double-</description>
</item>
<item>
<title>Filing of GSK plc 2025 Annual Report on Form 20-F</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/filing-of-gsk-plc-2025-annual-report-on-form-20-f</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/filing-of-gsk-plc-2025-annual-report-on-form-20-f</guid>
<pubDate>Fri, 06 Mar 2026 14:21:00 GMT</pubDate>
<description>GSK plc announced on March 6, 2026, that it has filed its Annual Report on Form 20-F with the Securities and Exchange Commission, containing audited financial statements for the year ended December 31, 2025. The report is accessible on GSK's website and the SEC's website, with a hard copy version expected around March 25, 2026. Shareholders can request a free hard copy of the complete audited financial statements from the company's registrars or ADR depositary.
Disclaimer*</description>
</item>
<item>
<title>GSK publishes Annual Report 2025</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/gsk-publishes-annual-report-2025</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/gsk-publishes-annual-report-2025</guid>
<pubDate>Thu, 05 Mar 2026 10:00:00 GMT</pubDate>
<description>GSK plc has published its Annual Report for the year ended 31 December 2025, making it available on its website and submitting it to the FCA's National Storage Mechanism. Shareholders who have elected for paper communications will receive a hard copy of the report and the Notice of Annual General Meeting 2026 around 25 March 2026, with the AGM Notice also being made available to other shareholders on the same date. This announcement serves to comply with FCA disclosure requirements, and the full</description>
</item>
<item>
<title>GSK completes acquisition of RAPT Therapeutics</title>
<link>https://6ix.com/company/glaxosmithkline-plc/news/gsk-completes-acquisition-of-rapt-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/glaxosmithkline-plc/news/gsk-completes-acquisition-of-rapt-therapeutics</guid>
<pubDate>Tue, 03 Mar 2026 15:00:00 GMT</pubDate>
<description>GSK plc has completed its acquisition of RAPT Therapeutics for an approximate aggregate equity value of $2.2 billion, with an upfront investment of approximately $1.9 billion net of cash acquired, gaining global rights to ozureprubart, a promising long-acting anti-immunoglobulin E monoclonal antibody in clinical development for food allergies. Ozureprubart, which targets IgE-mediated reactions, offers potential for less frequent dosing and could treat patients ineligible for existing therapies, </description>
</item>
</channel>
</rss>